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ABSTRACT
Stem cell transplantation (SCT) nephropathy is 1 cause of chronic kidney disease in patients after allogeneic
SCT. It is a thrombotic microangiopathic syndrome characterized by raised creatinine, hypertension, and
anemia. The difference with thrombotic thrombocytopenic purpura (TTP)-like syndromes is that it occurs
later than 3 months after SCT, has marked renal dysfunction, and occurs in the absence of other complications
or nephrotoxic medication. Total-body irradiation (TBI) in combination with previous chemotherapy is most
likely the cause. We describe 6 cases of SCT nephropathy that occurred in a cohort of 363 patients who
received myeloablative allogeneic SCT. All patients had TBI with shielding of the kidneys. We discuss the
course of the syndrome, treatment, and outcome of the patients.
© 2007 American Society for Blood and Marrow Transplantation
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CNTRODUCTION
One of the causes of chronic kidney disease after
tem cell transplantation (SCT) is a thrombotic mi-
roangiopathic condition called bone marrow trans-
lantation nephropathy or SCT nephropathy. The
yndrome was ﬁrst described in 1991, and might occur
n up to 20% of patients 1 year after allogeneic trans-
lantation. It is characterized by a sudden increase in
reatinine, microangiopathic hemolytic anemia, and
ypertension occurring typically after 6-12 months.
ereafter, a slower decline in kidney function, leading
o end-stage renal disease, but also stabilization can
ccur [1-3]. Time of onset, presentation, and his-
opathologic changes are the same as for radiation
ephritis seen previously after radiation for semino-
as [4]. Renal shielding during total-body irradiation
TBI) can decrease the chance of developing this syn-
rome at 2.5 years from around 30% to almost zero
5]. Because this syndrome occurs after a lower dose of
rradiation than classical radiation nephritis, other
auses might contribute to the pathogenesis [2]. In
xperimental rat models angiotensin converting enzyme F
38ACE) inhibitors can treat SCT nephropathy, and treat-
ent with ACE-inhibitors is recommended [6].
Here we describe the clinical course of 6 patients
ho developed SCT nephropathy in our SCT unit
ver a period of 11 years and discuss the literature.
ATERIALS AND METHODS
In this retrospective analysis 6 patients with SCT
ephropathy could be traced from 363 patients who
eceived myeloablative allogeneic stem cell transplan-
ation from January 1993 to January 2004. SCT ne-
hropathy was deﬁned as the triad of hypertension,
isproportionate severe anemia, and sudden rise in
erum creatinine with no apparent cause, occuring
ore than 3 months after transplantation [7].
The charts of the 6 patients were reviewed and
ospital course, posttransplant complications, and se-
um creatinines were noted. Patient characteristics
nd details of the clinical course are shown in Table 1.
reatinine values at different times are shown in
igure 1.
Table 1. Patient Characteristics of 6 Patients with SCT Nephropathy
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
Age at SCT 27 years 53 years 25 years 51 years 18 years 51 years
Sex female male female male male female
Disease AML, first remission CML, chronic phase AML, first remission AML, second remission ALL, first remission ALL, first remission
History no myocardial infarction no diabetes type II no hypertension
Previous treatment cytarabine,
idarubicine,
amsacrine
hydrea cytarabine, idarubicine cyatarabine idarubicine,
amsacrine,
mitoxantrone,
etoposide
vincristine, asparaginase, daunorubicine,
cytarabine, mercaptopurine,
etoposide cyclophosphamide
vincristine, asparaginase,
daunorubicine, cytarabine,
mitoxantrone
Conditioning standard* standard standard standard standard standard
ATG no no yes no no yes
Transplant sibling sibling MUD sibling sibling MUD
Baseline creatinine 53 mol/L 61 mol/L 147 mol/L 75 mol/L 56 mol/L 65 mol/L
ARF no yes yes yes yes yes
TTP no no yes no no no
aGVHD no no no no yes yes
cGVHD no no no no yes yes
Cyclosporine use 12 weeks 12 weeks 12 weeks 12 weeks 37 weeks 14 weeks
Timing SCTnp 8 months 14 months 32 months 36 months 12 months 13 months
Ultrasonography normal normal normal loss of parenchyma decreased right kidney normal
Kidney biopsy TMA not done not done not done TMA TMA, interstitial nephritis
Proteinuria 0.79 g/L 1.3 g/L 0.90 g/L 1.3 g/L 0 g/L 0.93 g/L
Hematuria /   / / 
Peak creatinine 987 mol/L 276 mol/L 454 mol/L 869 mol/L 861 mol/L 1211 mol/L
Lowest Hb 4.2 mmol/L 4.2 mmol/L 5.3 mmol/L 4.7 mmol/L 2.3 mmol/L 5.9 mmol/L
Lowest
thrombocytes
32  109/L 19  109/L 63  109/L 28  109/L 125  109/L 128  109/L
Highest tension 180/110 mmHg 220/110 mmHg 170/120 mmHg 220/130 mmHg 170/100 mmHg 160/105 mmHg
ACE inhibitor yes no yes yes yes yes
Last kidney
function
peritoneal dialysis GFR 22 mL/min/
1.73 m2
GFR 19 mL/min/
1.73 m2
peritoneal dialysis 15 mL/min/1.73 m2 29 mL/min/1.73 m2
Time of death and
cause
34 months sigmoid
perforation
15 months
multiorgan failure
alive alive 20 months pneumonia alive
SCT indicates stem cell transplantation; AML, acute myelogenous leukemia; CML, chronic myelogenous leukemia; ALL, acute lymphoblastic leukemia; ATG, antithymocyteglobulin; MUD, matched
unrelated donor; ARF, acute renal failure deﬁned as doubling of baseline creatinine within 3 months after SCT; TTP, thrombotic thrombocytopenic purpura within 3 months after SCT; aGVHD,
acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; SCTnp, stem cell transplantation nephropathy; TMA, thrombotic microangiopathy; GFR, glomerular ﬁltration rate,
calculated with MDRD equation: GFR  186.3  (serum creatinine)1.154  age0.203  (0.742 for women).
*Cyclophosphamide (60 mg/kg/day for 2 days), followed by total-body irradiation (600 cGy/day for 2 days) with partial shielding of the lungs (total lung dose 850 cGy) and partial shielding of the kidneys
(500 cGy/day for 2 days).
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Patient 1 was a 27-year-old woman who received
CT because of acute myelogenous leukemia (AML).
he was admitted 8 months after transplantation be-
ause of hypertension, raised creatinine, hemolytic
nemia with schistocytes, and thrombocytopenia. She
eceived ACE inhibition and a -blockade. Her cre-
tinine increased despite adequate treatment of hyper-
ension. Because of uremic pericarditis she started
eritoneal dialysis 16 months after SCT. She died of
ultiorgan failure resulting from perforation of the
igmoid 34 months after SCT.
Patient 2 was a 53-year-old man who received
CT because of chronic myelogenous leukemia
CML). Fourteen months after SCT he was admitted
ecause of abdominal pain, hemolytic anemia with
chistocytes, hypertension, thrombocytopenia, raised
reatinine, and epileptic seizures. Benzodiazepines led
o acute respiratory insufﬁciency and need for me-
hanical ventilation. Plasma exchange was started to
reat suspected thrombotic thrombocytopenic pur-
ura (TTP). Despite this treatment he died of multi-
rgan failure.
Patient 3 was a 25-year-old woman who received
CT because of AML. Nearly 3 years after transplan-
ation she was admitted because of hypertension,
aised creatinine, hemolytic anemia with schistocytes,
nd thrombocytopenia. Her blood pressure normal-
zed with a -blockade and ACE inhibition, but cre-
igure 1. Three different courses of stem cell transplantation
ephropathy.tinine increased slowly. She is now 3 years after Hransplantation and receives treatment for stage 4
hronic kidney disease with a glomerular ﬁltration
ate (GFR) of 19 mL/min/1.73 m2.
Patient 4 was a 51-year-old man who received
CT for AML in second remission. One year after
CT creatinine increased and persistent anemia with-
ut an obvious cause developed. Nearly 3 years after
CT hypertension was noted. He was admitted for
reatment of hypertension when creatinine was 472
mol/L 2 years later. ACE inhibition, diuretics, and a
-blockade were started, which led to further rise in
reatinine and end-stage renal disease. He started
eritoneal dialysis more then 5 years after SCT.
early 10 years after SCT he is now in good clinical
ondition.
Patient 5 was a 18-year-old man who received
CT because of acute lymphoblastic leukemia (ALL).
ne year after transplantation he developed autoim-
une hemolytic anemia with hypertension and creat-
nine of 400 mol/L. After starting with ACE inhibi-
ion the creatinine stabilized at 250 mol/L. The
emolytic anemia did not respond to treatment. He
ied 20 months after SCT because of pneumonia.
Patient 6 was a 51-year-old- woman who received
CT because of ALL. Eight months later a -block-
de was started because of recurrence of hypertension.
ive months later ACE inhibition and diuretics were
tarted because of persistence of hypertension, raised
reatinine, and anemia, and were discontinued shortly
ereafter because of worsening of the kidney function.
fter an initial decrease her creatinine rose again and
iver enzyme abnormalities developed. After discon-
inuation of valaciclovir and treatment with cortico-
teroids, creatinine decreased. Hypertension was
reated with calcium antagonist, and with this treat-
ent kidney function stabilized at GFR of 28 mL/
in/1.73 m2.
ISCUSSION
The diagnosis of individual patients with throm-
otic microangiopathy and renal dysfunction after al-
ogeneic SCT can be difﬁcult. Different forms of
verlapping thrombotic microangiopathic syndromes
ave been described. A patient with microangiopathic
emolytic anemia after SCT may therefore be given
he diagnosis SCT nephropathy [1,7-18], radiation
ephropathy [2,19-22], hemolytic uremic syndrome
HUS) [23-28], or TTP [23,28-30]. Pettitt and Clark
26] made a classiﬁcation of post-SCT thrombotic
icroangiopathy: (1) multifactorial fulminant throm-
otic microangiopathy, (2) cyclosporine nephro-
oxicity with microangiopathic hemolytic anemia,
3) cyclosporine neurotoxicity with microangiopathic
emolytic anemia, and (4) conditioning-associated
US.The ﬁrst 3 syndromes resemble classical TTP
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Stem Cell Transplantation Nephropathy 641nd usually develop within 3 months after SCT. The
iagnosis of TTP is uncertain following SCT because
f the presence of multiple SCT-associated complica-
ions [29], and the absence of generally accepted de-
ailed diagnostic criteria [30]. It is even stated that
linical signs of a systemic infection or graft-versus-
ost disease (GVHD) mimic TTP, and that TTP is
ot a speciﬁc sequla after SCT [28]. Multifactorial
hrombotic microangiopathy or TTP on the back-
round of GVHD, infections, or other complications
ost-SCT has a high mortality [26]. Plasmapheresis or
lasma infusion have shown little efﬁcacy in TTP-like
onditions following SCT, in contrast to classical
TP [23,31]. Treatment of associated complications
s recommended [28]. When patients are receiving
yclosporine, this should be discontinued, but this can
ead to deterioration of GVHD. Alternative immuno-
uppression with corticosteroids should be considered
26]. Cyclosporine nephrotoxicity with microangio-
athic hemolytic anemia is a form of TTP that is
eadily reversible on discontinuation of cyclosporine
nd treatment of hypertension, and thus has a good
rognosis [26].
Conditioning-associated HUS, the fourth condi-
ion mentioned by Petitt and Clark, is almost similar
o SCT nephropathy or radiation nephritis, with pre-
ominantly raised creatinine levels and hypertension
ccuring more than 3 months after SCT, with low
ortality but frequent residual renal impairment [26].
The major difference between TTP-like syn-
romes with renal impairment (multifactorial throm-
otic microangiopathy and cyclosporine nephrotoxic-
ty with microangiopathic hemolytic anemia) and
CT nephropathy (radiation nephritis or condition-
ng-associated HUS) is the time of occurrence, with
TP usually occuring within 3 months after SCT and
CT nephropathy occurring after 3 months. Other
ifferences are that renal impairment and hyperten-
ion are a prerequisite for SCT nephropathy [7], but
an be less dominant in TTP, and that SCT nephro-
athy occurs in the absence of active complications or
oxic medication [3], whereas TTP often occurs in
ssociation with complications like GVHD and infec-
ions [28], or cyclosporine [32,33].
The hallmark of these syndromes is thrombotic
icroangiopathy. In SCT recipients, multiple in-
ults may lead to the initiation of endothelial cell
njury or dysfunction. These can be conditioning
egimens with high-dose chemotherapy or TBI, and
ncreased levels of cytokines in association with
GVHD or sinusoidal occlusion syndrome [32]. In
ddition, cyclosporine may promote procoagulant
hanges in the endothelium by increasing the re-
ease of thromboxane A2 and thromboplastin and
ncreasing ADP, collagen, and adrenaline-induced
latelet aggregation and factor VII activity and de-
reasing the production of prostacycline, thrombo- podulin, and protein C [30]. TBI containing con-
itioning regimens seem to be the major risk factor
or SCT nephropathy [34].
In our study SCT nephropathy developed in 6 of
63 patients (1.7%). The incidence of SCT nephro-
athy after allogeneic SCT in adults varies between
% and 29% [3,18,19,35,36], with low incidence if the
idneys are shielded [5]. The low incidence of our
ohort conﬁrms the efﬁcacy of renal shielding in re-
ucing the incidence of SCT nephropathy.
The ﬁrst 3 cases show a condition resembling
lassical TTP, but it is SCT nephropathy because of
he time of occurrence, the marked hypertension, and
ncrease in serum creatinine. The last 3 cases lack the
nitial event with thrombocytopenia, but are SCT
ephropathy because of the combination of anemia,
ypertension, and renal impairment in the absence of
n obvious cause. In the last 2 patients thrombotic
icroangiopathy was conﬁrmed by renal biopsies.
revious studies have recognized 3 different courses of
CT nephropathy: acute decline in kidney function
patients 1-3), a more gradual decline in kidney func-
ion (patient 4), and an initial decline in kidney func-
ion followed by stabilization at a reduced GFR (pa-
ients 5 and 6) [7] (Figure 1). SCT nephropathy is a
erious condition because it can lead to end-stage
enal disease [8], but acute mortality is lower than in
omplications-associated TTP-like conditions [26]. In
ur case-series, 2 patients developed end-stage renal
isease, 3 patients developed severe kidney disease
tage 4 (GFR 15-29 mL/min/1.73m2), and 1 patient
ied of SCT nephropathy.
Angiotensin converting enzyme inhibition stabi-
ized kidney function in 1 of 5 patients and had no
ffect in the other 4 patients. These results are not
ery promising, but because no better treatment is
vailable, ACE inhibition remains the treatment of
hoice. Plasma exchange therapy showed not to be
ffective in the 1 patient who received this treatment,
s was described in earlier studies [30].
Anemia in SCT nephropathy can be caused by
hrombotic microangiopathy or erytropoeitin deﬁ-
iency in a later phase [1,3]. Erythropoietin deﬁ-
iency in patients with SCT nephropathy is more
ronounced than observed in patients with an
quivalent decrease in GFR by another cause [17].
herefore, erythropoietin is recommended for
reatment of anemia in patients with chronic SCT
ephropathy [2]. Our 2 patients with end-stage re-
al disease received this treatment with successful
ncrease in hemoglobin.
Although nephrotoxic drugs (eg, cyclosporine and
mphotericin B) can cause acute renal failure [37,38],
CT nephropathy seems not inﬂuenced by them [39].
here was no direct relationship in use of nephrotoxic
rugs and occurrence of SCT nephropathy in our
atients, except for the sixth patient, who had a com-
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S. Kersting and L. F. Verdonck642ination of thrombotic microangiopathy and intersti-
ial nephritis because of valaciclovir.
Severe proteinuria is not a sign of SCT nephro-
athy, and was absent in our patients. Nephrotic syn-
rome in association with chronic GVHD (cGVHD)
s an extremely rare complication after myeloablative
CT, but is now more often recognized after non-
yeloablative SCT, even in the absence of cGVHD
40]. Two of our patients had chronic GVHD, but
here was no relationship with development of SCT
ephropathy.
In summary, SCT nephropathy is 1 of the throm-
otic microangiopathic syndromes occuring after
CT. It occurs later than TTP-like syndromes, and is
haracterized by renal dysfunction, anemia, and hy-
ertension, without an obvious cause. It can lead to an
cute decline in kidney function or run a more gradual
ourse. Although acute mortality is not so high, it is a
erious condition because it can lead to end-stage
enal disease. TBI in conditioning regimens is most
ikely the cause. ACE inhibition is recommended, but
ertainly cannot prevent deterioration of kidney func-
ion in many patients. Treatment with erythropoietin
elieves anemia seen later in these patients.
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